please share a diagram showing mechanism of action of Avlayah
Checking Date & Time
Reading File
Searching the Web
Avlayah drug mechanism of action
Finding Sources
Searching Images
tividenofusp alfa Hunter syndrome MPS II mechanism of action enzyme replacement therapy blood brain barrier
Searching the Web
tividenofusp alfa Avlayah mechanism of action IDS enzyme BBB transferrin receptor diagram
Finding Sources
Generating Image
what cause MDR Hiv?
Checking Date & Time
Reading File
Finding Sources
Finding Sources
Reading File
Finding Sources
Reading File
Reading File
Reading File
Reading File
Reading File
Loading Image
I have comprehensive information to give a thorough answer. Here it is:
Causes of Multidrug-Resistant (MDR) HIV
MDR HIV arises from a combination of intrinsic viral biology and external (host/treatment) factors. The key causes are:
1. Error-Prone Reverse Transcriptase (The Core Driver)
HIV's reverse transcriptase (RT) lacks proofreading activity (unlike cellular DNA polymerases). This results in a mutation rate of approximately 3 × 10⁻⁵ per nucleotide per replication cycle. Combined with HIV's massive replication rate — generating 10⁹ to 10¹⁰ virions per day — this means millions of mutant variants (called quasi-species) are produced daily within a single infected individual. Any mutation that confers drug resistance will be positively selected under drug pressure.
— Janeway's Immunobiology, 10e
2. Pre-existing Resistant Variants (Before Treatment Begins)
Because of the enormous number of daily variants, resistant mutants pre-exist in the viral population even before any drug is given. Estimates indicate that variants with single resistance mutations to individual antiretroviral agents are already present at the start of therapy. When a drug is introduced, it simply selects for these pre-existing mutants.
— Goldman-Cecil Medicine
3. Sequential or Inadequate Monotherapy
Using single drugs or suboptimal regimens is a major driver of MDR:
- Resistance to some protease inhibitors requires only a single mutation — resistance emerges within days of starting monotherapy
- Resistance to some RT inhibitors also develops rapidly with monotherapy
- Resistance to zidovudine (AZT) takes months, as it requires 3–4 mutations in RT simultaneously
The chart below illustrates how fast resistance emerges under monotherapy with a protease inhibitor:
— Janeway's Immunobiology, 10e, Fig. 13.47
4. Poor Adherence to ART
Subtherapeutic drug levels due to missed doses or incomplete adherence allow viral replication to continue in the presence of drugs — the ideal conditions for selecting resistant mutants. The emergence of resistance is proportional to the frequency of pre-existing variants and their growth advantage under drug pressure.
— Sherris & Ryan's Medical Microbiology, 8e
5. Transmitted (Primary) Resistance
MDR HIV can be acquired directly from another person who is already infected with resistant strains. This is called transmitted drug resistance — a patient may be treatment-naive but already carry MDR virus. This is why HIV genotyping is performed before initiating ART.
6. Accumulation of Resistance Mutations Across Drug Classes
With repeated treatment failures or sequential regimen changes, the virus accumulates mutations targeting multiple drug classes simultaneously:
| Drug Class | Key Resistance Mutations |
|---|---|
| NRTIs (e.g., AZT, 3TC) | M184V, K65R, thymidine analog mutations (TAMs) |
| NNRTIs (e.g., efavirenz) | K103N, Y181C (single mutation often sufficient) |
| Protease Inhibitors | Multiple active-site mutations (accumulate stepwise) |
| Integrase Inhibitors | N155H, Q148H/R/K, G140S |
Why HAART/cART Prevents MDR
Combination antiretroviral therapy (cART/HAART) targets multiple enzymes simultaneously. The probability of simultaneous resistance mutations across all targeted proteins is virtually nil — making full MDR extremely unlikely when the patient is fully adherent to a well-chosen regimen.
"It is more difficult for HIV to develop resistance to multiple drugs with multiple target enzymes. Multidrug-resistant HIV strains are likely to be much weaker than the parent strains." — Medical Microbiology, 9e
Summary of Causes
| Cause | Mechanism |
|---|---|
| Error-prone RT (no proofreading) | High baseline mutation rate |
| Massive viral replication | 10⁹–10¹⁰ virions/day → quasi-species swarm |
| Pre-existing resistant variants | Selected under drug pressure |
| Monotherapy / inadequate regimens | Single-target drugs easily overcome |
| Poor adherence | Subtherapeutic levels allow replication + selection |
| Transmitted resistance | Acquired from a partner with MDR HIV |
| Sequential regimen changes | Accumulation of multi-class resistance mutations |
why NRTI are prone to resistance?
Finding Sources
Finding Sources
Your credits are exhausted. Your daily credits reset tomorrow, or you can purchase a top-up for more.
This is a shared conversation. Sign in to Orris to start your own chat.